The data suggest that complex interrelated pathways participate in the acquisition of EGFR-TKI resistance, and that modulating AICDA and NF-κB signaling may overcome limitations associated with treatment of EGFR-TKI-resistant lung cancers. This evidence concerns the gene NFKB1 and lung carcinoma.